Anecortave Acetate Risk-Reduction Trial (AART)

A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.

Inclusion Criteria:

• Dry AMD study eye, Wet AMD non-study eye.
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Age
• Other protocol-defined exclusion criteria may apply.